航空航天医学杂志
航空航天醫學雜誌
항공항천의학잡지
Journal of Aerospace Medicine
2015年
11期
1328-1329
,共2页
依达拉奉%急性脑梗死%自由基
依達拉奉%急性腦梗死%自由基
의체랍봉%급성뇌경사%자유기
Edaravone%Acute cerebral infarction%Free radical
目的 探讨依达拉奉治疗急性脑梗死的临床疗效,分析研究其安全性. 方法 选取神经内科2013 年10月~2014年10月收治的108例急性脑梗死患者,随机分为观察组( n=54 )和对照组( n=54 ) ,两组患者均给予静脉滴注丹参川芎嗪、神经保护剂、口服阿司匹林肠溶片、控制血压、血糖、调节血脂等常规治疗,观察组在对照组治疗基础上加用依达拉奉注射液,每天2次,疗程2周. 在治疗前后,对两组患者采用神经功能缺损评分( NIHSS)和日常生活能力指教评分( ADL)进行疗效评估及安全性分析. 结果 经过2周治疗,观察组NHISS、ADL评分均优于对照组,观察组总有效率显著高于对照组,差异具有统计学意义( P<0.05 ) ,两组患者治疗观察均未见明显不良反应. 结论 依达拉奉注射液能改善急性脑梗死患者的神经功能,且安全性较高.
目的 探討依達拉奉治療急性腦梗死的臨床療效,分析研究其安全性. 方法 選取神經內科2013 年10月~2014年10月收治的108例急性腦梗死患者,隨機分為觀察組( n=54 )和對照組( n=54 ) ,兩組患者均給予靜脈滴註丹參川芎嗪、神經保護劑、口服阿司匹林腸溶片、控製血壓、血糖、調節血脂等常規治療,觀察組在對照組治療基礎上加用依達拉奉註射液,每天2次,療程2週. 在治療前後,對兩組患者採用神經功能缺損評分( NIHSS)和日常生活能力指教評分( ADL)進行療效評估及安全性分析. 結果 經過2週治療,觀察組NHISS、ADL評分均優于對照組,觀察組總有效率顯著高于對照組,差異具有統計學意義( P<0.05 ) ,兩組患者治療觀察均未見明顯不良反應. 結論 依達拉奉註射液能改善急性腦梗死患者的神經功能,且安全性較高.
목적 탐토의체랍봉치료급성뇌경사적림상료효,분석연구기안전성. 방법 선취신경내과2013 년10월~2014년10월수치적108례급성뇌경사환자,수궤분위관찰조( n=54 )화대조조( n=54 ) ,량조환자균급여정맥적주단삼천궁진、신경보호제、구복아사필림장용편、공제혈압、혈당、조절혈지등상규치료,관찰조재대조조치료기출상가용의체랍봉주사액,매천2차,료정2주. 재치료전후,대량조환자채용신경공능결손평분( NIHSS)화일상생활능력지교평분( ADL)진행료효평고급안전성분석. 결과 경과2주치료,관찰조NHISS、ADL평분균우우대조조,관찰조총유효솔현저고우대조조,차이구유통계학의의( P<0.05 ) ,량조환자치료관찰균미견명현불량반응. 결론 의체랍봉주사액능개선급성뇌경사환자적신경공능,차안전성교고.
Objective To explore the clinical efficacy of edaravone injection for the treatment of acute cerebral in -farction, and to analyze the safety.Methods 208 cases of acute cerebral infarction patients who treated in our hospital from January 2014 to Decemeber 2014 were selected, and randomly divided into the observation group (n=54) and con-trol group(n=54).All the patients in the two groups were treated with conventional treatment , such as intravenous infu-sion of salvia tetramethylpyrazine and neuroprotective agents , oral aspirin enteric -coated tablets , blood pressure and blood sugar controling , and blood lipids regulating , and the patients in the observation group were treated with edaravone injection based on the conventional treatment in the control group , twice per day , 2 weeks a cycle.The efficacy and safe-ty were evaluated and analyzed before and after treatment with National Institute of Health stroke scale ( NIHSS) and ac-tivity of daily living (ADL) score.Results After treatment for 2 weeks, the NIHSS and ADL score of the observation group were better than those of the control group , and the effective rate of the observation group was significantly higher than that of the control group (P<0.05).There was no adverse reaction in two groups.Conclusions Edaravone injec-tion can improve the neurological function of the patients with acute cerebral infarction with high security .
